Loading...
Albuterol has been the go-to asthma rescue inhaler for decades, but it does not prevent asthma exacerbations. Guidelines now recommend albuterol plus an inhaled corticosteroid (ICS) as a rescue inhaler and formoterol/ICS as a rescue inhaler or maintenance and reliever therapy.
In a systematic review of 27 randomized trials with more than 50,000 patients, researchers examined asthma outcomes in patients who used short-acting β-agonists (SABAs; i.e., albuterol, salbutamol, or terbutaline) versus ICS/SABA or ICS/formoterol. For patients at highest risk, ICS/formoterol lowered relative risk for severe asthma exacerbations by 35%, and ICS/SABA lowered relative risk by 16%, compared with SABA monotherapy. Additionally, moderate evidence suggested …